Last reviewed · How we verify
NCT05599880
The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
Phase 2 trial testing Bortezomib in Relapsed/Refractory Immune Thrombocytopenia in 29 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 7 July 2023 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 4 locations across South Korea |
Drugs / interventions tested
- Bortezomib (bortezomib) — full drug profile →
Conditions studied
- Relapsed/Refractory Immune Thrombocytopenia — all drugs for Relapsed/Refractory Immune Thrombocytopenia →
Sponsor
Seoul National University Hospital
Who can join
19 and older, any sex, with Relapsed/Refractory Immune Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
to investigate efficacy and safety evaluation of bortezomib in patients with relapsed/refractory immune thrombocytopenia
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Rituximab resistance in ITP and beyond.
Xiao Z, Murakhovskaya I. · · 2023 · cited 11× · PMID 37575230 · DOI 10.3389/fimmu.2023.1215216 -
On the horizon: upcoming new agents for the management of ITP.
Lambert MP. · · 2024 · cited 2× · PMID 39644072 · DOI 10.1182/hematology.2024000596 -
Refractory ITP: revisiting definitions, diagnostics, and management paradigms.
Panch SR, Raman G, Bussel JB. · · 2025 · PMID 41347997 · DOI 10.1182/hematology.2025000720
Verify or expand the search:
- PubMed search for NCT05599880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bortezomib
Trials testing the same drug.
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
- NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an · Phase 2 · not yet recruiting
- NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05599880 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 2 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05599880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing